Cutaneous Vasculitis During Secukinumab Treatment
Secukinumab is an inhibitor of interleukin IL-17A, and is mainly used in the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. Although rarely, this drug may induce paradoxical reactions, such as cutaneous vasculitis. Worldwide, only four previous cases of vasculitis induced by...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMC MEDIA SRL
2020-07-01
|
| Series: | European Journal of Case Reports in Internal Medicine |
| Online Access: | https://www.ejcrim.com/index.php/EJCRIM/article/view/1815 |
| _version_ | 1811314038355787776 |
|---|---|
| author | Camila da Silva Cendon Duran Mittermayer Barreto Santiago |
| author_facet | Camila da Silva Cendon Duran Mittermayer Barreto Santiago |
| author_sort | Camila da Silva Cendon Duran |
| collection | DOAJ |
| description | Secukinumab is an inhibitor of interleukin IL-17A, and is mainly used in the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. Although rarely, this drug may induce paradoxical reactions, such as cutaneous vasculitis. Worldwide, only four previous cases of vasculitis induced by secukinumab have been reported. We herein report the first case described in Brazil of cutaneous vasculitis due to secukinumab in a patient with peripheral spondyloarthritis who demonstrated good resolution after withdrawal of the drug and initiation of etanercept. Clinicians should be aware of this rare but potentially serious adverse effect of secukinumab. |
| first_indexed | 2024-04-13T11:04:57Z |
| format | Article |
| id | doaj.art-d36e281922a7457b9ff3c236c3ba1428 |
| institution | Directory Open Access Journal |
| issn | 2284-2594 |
| language | English |
| last_indexed | 2024-04-13T11:04:57Z |
| publishDate | 2020-07-01 |
| publisher | SMC MEDIA SRL |
| record_format | Article |
| series | European Journal of Case Reports in Internal Medicine |
| spelling | doaj.art-d36e281922a7457b9ff3c236c3ba14282022-12-22T02:49:18ZengSMC MEDIA SRLEuropean Journal of Case Reports in Internal Medicine2284-25942020-07-0110.12890/2020_0018151442Cutaneous Vasculitis During Secukinumab TreatmentCamila da Silva Cendon Duran0Mittermayer Barreto Santiago1Hospital das Clínicas da Universidade de São Paulo, São Paulo, BrazilHospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Bahia, BrazilSecukinumab is an inhibitor of interleukin IL-17A, and is mainly used in the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. Although rarely, this drug may induce paradoxical reactions, such as cutaneous vasculitis. Worldwide, only four previous cases of vasculitis induced by secukinumab have been reported. We herein report the first case described in Brazil of cutaneous vasculitis due to secukinumab in a patient with peripheral spondyloarthritis who demonstrated good resolution after withdrawal of the drug and initiation of etanercept. Clinicians should be aware of this rare but potentially serious adverse effect of secukinumab.https://www.ejcrim.com/index.php/EJCRIM/article/view/1815 |
| spellingShingle | Camila da Silva Cendon Duran Mittermayer Barreto Santiago Cutaneous Vasculitis During Secukinumab Treatment European Journal of Case Reports in Internal Medicine |
| title | Cutaneous Vasculitis During Secukinumab Treatment |
| title_full | Cutaneous Vasculitis During Secukinumab Treatment |
| title_fullStr | Cutaneous Vasculitis During Secukinumab Treatment |
| title_full_unstemmed | Cutaneous Vasculitis During Secukinumab Treatment |
| title_short | Cutaneous Vasculitis During Secukinumab Treatment |
| title_sort | cutaneous vasculitis during secukinumab treatment |
| url | https://www.ejcrim.com/index.php/EJCRIM/article/view/1815 |
| work_keys_str_mv | AT camiladasilvacendonduran cutaneousvasculitisduringsecukinumabtreatment AT mittermayerbarretosantiago cutaneousvasculitisduringsecukinumabtreatment |